{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:02:17Z","timestamp":1762956137533,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen City Funding for Basic Research Innovation Project","award":["JCYJ20150403100317057"],"award-info":[{"award-number":["JCYJ20150403100317057"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM201512033"],"award-info":[{"award-number":["SZSM201512033"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5898-4","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T11:03:20Z","timestamp":1562756600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1\/AKT1\/NF\u03baB pathway"],"prefix":"10.1186","volume":"19","author":[{"given":"Xiaorong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huirong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanfang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunqing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-9852","authenticated-orcid":false,"given":"Yunsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"issue":"3\u20134","key":"5898_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000363434","volume":"132","author":"N Pemmaraju","year":"2014","unstructured":"Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014;132(3\u20134):298\u2013306.","journal-title":"Acta Haematol"},{"issue":"9976","key":"5898_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447\u201359.","journal-title":"Lancet"},{"issue":"3","key":"5898_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"issue":"3","key":"5898_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.beha.2009.04.004","volume":"22","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Saglio G. CML: a model for targeted therapy. Best Pract Res Clin Haematol. 2009;22(3):285\u201394.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"5898_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2040620714560305","volume":"6","author":"MJ Mauro","year":"2015","unstructured":"Mauro MJ, Davis C, Zyczynski T, Khoury HJ. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia. Ther Adv Hematol. 2015;6(1):3\u201314.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"5898_CR6","first-page":"299","volume":"14","author":"D Barrett","year":"2012","unstructured":"Barrett D, Brown VI, Grupp SA, Teachey DT. Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs. 2012;14(5):299\u2013316.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"5898_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.febslet.2010.12.045","volume":"585","author":"Y Gu","year":"2011","unstructured":"Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu Y, Ouyang Y, He Z. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett. 2011;585(6):881\u20137.","journal-title":"FEBS Lett"},{"issue":"1\u20132","key":"5898_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11010-014-2217-x","volume":"398","author":"X Liu","year":"2015","unstructured":"Liu X, Wang C, Gu Y, Zhang Z, Zheng G, He Z. TCRP1 contributes to cisplatin resistance by preventing pol beta degradation in lung cancer cells. Mol Cell Biochem. 2015;398(1\u20132):175\u201383.","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"5898_CR9","doi-asserted-by":"publisher","first-page":"e51413","DOI":"10.1371\/journal.pone.0051413","volume":"7","author":"B Peng","year":"2012","unstructured":"Peng B, Gu Y, Xiong Y, Zheng G, He Z. Microarray-assisted pathway analysis identifies MT1X & NFkappaB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma. PLoS One. 2012;7(12):e51413.","journal-title":"PLoS One"},{"issue":"2","key":"5898_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pep.2012.02.002","volume":"82","author":"B Peng","year":"2012","unstructured":"Peng B, Yi S, Gu Y, Zheng G, He Z. Purification and biochemical characterization of a novel protein-tongue cancer chemotherapy resistance-associated protein1 (TCRP1). Protein Expr Purif. 2012;82(2):360\u20137.","journal-title":"Protein Expr Purif"},{"issue":"1\u20132","key":"5898_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11010-011-0880-8","volume":"357","author":"Y Gu","year":"2011","unstructured":"Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, He Z. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem. 2011;357(1\u20132):107\u201313.","journal-title":"Mol Cell Biochem"},{"issue":"13","key":"5898_CR12","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1093\/nar\/gkg584","volume":"31","author":"JC Obenauer","year":"2003","unstructured":"Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003;31(13):3635\u201341.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"5898_CR13","first-page":"242","volume":"15","author":"X Guo","year":"2007","unstructured":"Guo X, Pan L, Hou LF, Wang YJ, Guo HM, Yang L, Wang ZW, Sun Y, Li DL. Regulative effects of ERK and P38 signal transduction pathway on cell cycle in chronic myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15(2):242\u20137.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"5898_CR14","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.3892\/etm.2016.3768","volume":"12","author":"L Li","year":"2016","unstructured":"Li L, Zhou ZY, Xie W. Expression and functions of the STAT3-SCLIP pathway in chronic myeloid leukemia cells. Exp Ther Med. 2016;12(5):3381\u20136.","journal-title":"Exp Ther Med"},{"key":"5898_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pharmthera.2016.12.001","volume":"172","author":"JS Brown","year":"2017","unstructured":"Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol Ther. 2017;172:101\u201315.","journal-title":"Pharmacol Ther"},{"issue":"5670","key":"5898_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.","journal-title":"Science"},{"issue":"12","key":"5898_CR17","doi-asserted-by":"publisher","first-page":"15859","DOI":"10.1007\/s13277-016-5413-3","volume":"37","author":"Jing Hu","year":"2016","unstructured":"Hu J, Feng M, Liu ZL, Liu Y, Huang ZL, Li H, Feng WL. Potential role of Wnt\/beta-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between beta-catenin and BCR-ABL. Tumour Biol. 2016. \n                    https:\/\/doi.org\/10.1007\/s13277-016-5413-3\n                    \n                  .","journal-title":"Tumor Biology"},{"issue":"5","key":"5898_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/cgt.2014.65","volume":"22","author":"Q Li","year":"2015","unstructured":"Li Q, Wu Y, Fang S, Wang L, Qi H, Zhang Y, Zhang J, Li W. BCR\/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts. Cancer Gene Ther. 2015;22(5):227\u201337.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"5898_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/iub.1351","volume":"67","author":"X Zhang","year":"2015","unstructured":"Zhang X, Dong W, Zhou H, Li H, Wang N, Miao X, Jia L. alpha-2,8-Sialyltransferase is involved in the development of multidrug resistance via PI3K\/Akt pathway in human chronic myeloid leukemia. IUBMB Life. 2015;67(2):77\u201387.","journal-title":"IUBMB Life"},{"key":"5898_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40880-016-0108-0","volume":"35","author":"ZJ Kang","year":"2016","unstructured":"Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:48.","journal-title":"Chin J Cancer"},{"issue":"1","key":"5898_CR21","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1038\/s41598-017-03763-0","volume":"7","author":"X Jia","year":"2017","unstructured":"Jia X, Zhang Z, Luo K, Zheng G, Lu M, Song Y, Liu H, Qiu H, He Z. TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer. Sci Rep. 2017;7(1):3744.","journal-title":"Sci Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5898-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T23:13:20Z","timestamp":1594250000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5898-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5898"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5898-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Laboratory Animal Ethics Committee of the Shenzhen Advanced Institute of the Chinese Academy of Sciences (No. SIAT-IRB-160622-LXR-A0234). All procedures involving animals were performed in accordance with the experimental animal ethical standards of Shenzhen Advanced Institute of the Chinese Academy of Sciences. The study was approved by the ethics committee of Shenzhen Children\u2019s hospital (No. 2018010). Informed consents were signed by the parents of every child before the blood collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The parents of every child had signed the consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"679"}}